摘要
新型冠状病毒肺炎(COVID-19)具有流行性广、传染性强、发病急骤和病情危重等特点,目前对于COVID-19主要采用中西医结合治疗方法,临床效果显著,凸显中医药在抗病毒方面的优势。早期大量药理药效学和临床研究证实温郁金具有显著抗病毒作用,对病毒性肺炎、上呼吸道感染等呼吸系统疾病疗效确切。此外,温郁金还具有一定抗肺纤维化作用,提示其可能会对由COVID-19引发的肺损伤有缓解或治疗作用。通过对温郁金抗病毒的化学成分、药理作用、机制研究和临床应用进行总结梳理,并从中医角度分析COVID-19的病因机制和辨证治法,以期为温郁金临床治疗COVID-19和后续相关药物研发提供参考。
Coronavirus disease 2019(COVID-19)has the characteristics of widespread epidemic,strong infectivity,rapid onset and critical illness.At present,many hospitals adopt integrated Chinese and Western medicine treatment methods,which have significant clinical effects,highlighting the antiviral effect of traditional Chinese medicine in.A large number of early pharmacological and pharmacodynamic and clinical research results have confirmed that medicinal plants Curcuma wenyujin has a significant antiviral effect,and it is effective for respiratory diseases such as viral pneumonia and upper respiratory tract infection.In addition,medicinal plants C.wenyujin also has a certain anti-pulmonary fibrosis effect,suggesting that it may alleviate or treat lung injury caused by COVID-19.Through summarizing and combing the chemical composition,pharmacological action,mechanism research and clinical application of antiviral of medicinal plants C.wenyujin,and analyzing the etiology mechanism and dialectical treatment of COVID-19 from the perspective of traditional Chinese medicine,with a view to providing a reference for the clinical treatment of COVID-19 infection and subsequent related drug development.
作者
秦宇雯
赵祺
赵宇烁
任仙樱
鲍康德
李校堃
姜程曦
QIN Yu-wen;ZHAO Qi;ZHAO Yu-shuo;REN Xian-ying;BAO Kang-de;LI Xiao-kun;JIANG Cheng-xi(Institute of Life Sciences,Wenzhou University,Wenzhou 325035,China;College of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Zhejiang Collaborative Innovation Center of Biomedicines,Wenzhou 325035,China;Hefei Future Drug Development Co.,Ltd.,Hefei 230000,China)
出处
《中草药》
CAS
CSCD
北大核心
2020年第8期1977-1983,共7页
Chinese Traditional and Herbal Drugs
基金
浙江大学新型冠状病毒肺炎(COVID-19)应急科研专项(2020XGZX029)
温州市新型冠状病毒肺炎疫情防控应急攻关项目(ZY202002)
合肥市未来药物开发有限公司—浙大应急科研专项横向课题(2020XGZX029)
云南大理药业股份有限公司横向课题(KJHX1603)。